Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T16:31:51.342Z Has data issue: false hasContentIssue false
  • English
  • Français

Preliminary study on changes in BDNF in patients with depression after percutaneous coronary intervention

Published online by Cambridge University Press:  19 July 2023

S. Medved ,
S. Sović ,
L. Ganoci ,
N. Božina ,
M. Šagud ,
J. Bulum  and
A. Mihaljević-Peleš
S. Medved*
Affiliation:
Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb
S. Sović
Affiliation:
Department of Medical Statistics, Epidemiology and Medical Informatics, “Andrija Štampar” School of Public Health
L. Ganoci
Affiliation:
Department of Laboratory Diagnostics, University Hospital Centre Zagreb
N. Božina
Affiliation:
Department of Laboratory Diagnostics, University Hospital Centre Zagreb School of Medicine University of Zagreb
M. Šagud
Affiliation:
Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb School of Medicine University of Zagreb
J. Bulum
Affiliation:
School of Medicine University of Zagreb Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia
A. Mihaljević-Peleš
Affiliation:
Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depression and coronary artery disease (CAD) are often comorbid conditions. The presence of depression significantly interferes with the recovery after CAD therapy intervention, such as percutaneous coronary intervention (PCI), one of the most common medical procedures in developed countries. Brain derived neurotrophic factor (BDNF) has a major role in angiogenesis and neuromodulation. Its levels were previously shown to be reduced in patients with depression, and latest studies indicate similar in patients with CAD. However, the correlation of BDNF levels and depression after CAD treatment is unknown.

Objectives

The aim of this preliminary study is to assess the changes in BDNF levels in patients with depressive symptoms during a six-month period upon PCI.

Methods

Antidepressant-free participants that underwent PCI with stent placement due to myocardial infarction or angina pectoris were enrolled in the study. Depressive symptoms were evaluated at baseline using the Beck’s Depression Inventory II (BDI-II) with a cut-off score ≥20 indicating moderate depression. Serum BDNF levels were measured from blood samples drawn a day after (baseline) and six-months upon a successful PCI without complications. The t-test for dependent samples was used with marked significant differences at p<0,05.

Results

Altogether, 76 participants were included in the study, of which 25 finished a six-month follow-up. Participants with BDI-II≥20 at baseline had higher serum BDNF levels in the second measurement (M=23,12, SD=6,20; M=32,02, SD=12,26, respectively). No significant difference was found in serum BDNF levels in measurements between participants with and without depressive symptoms (t=0,33, p=0,74; t=-1,40, p=0,18, respectively). Statistically significant difference was found between serum BDNF in the first and second measurement in the overall sample (t=-2,28, p=0,03) and in participants with baseline moderate depressive symptoms (t=-2,46, p= 0,03), but not in those without (t=-0,59, p=0,57).

Conclusions

Serum BDNF levels in participants with baseline moderate depressive symptoms increased after a six-month period upon successful PCI treatment, whereas that trend was not observed in participants without depressive symptoms. This highlights the potential synergistic role of BDNF in comorbid depression and CAD.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S68
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.